|
1) Ebstein W. Zur therapie des diabetes mellitus, insbesondere uber die Anwendung des salicylsauren natron bei demselben. Berlin Klin-Wochenschrift. 1876; 13: 337-40
|
|
|
|
|
2) Williamson R. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J. 1901; 1: 760-2
|
|
|
|
|
|
3) Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-9
|
|
|
|
|
4) Pradhan AD, Manson JE, Rifai N, et al. C- reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327-34
|
|
|
|
|
|
5) Visser M, Bouter MN, McQuillan GM, et al. Elevated c-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131-5
|
|
|
|
|
|
6) Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51: 1131-7
|
|
|
|
|
|
7) Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factor-α in sera of obese patients: Fall with weight loss. J Clin Endocrinol Metab. 1998; 83: 2907-10
|
|
|
|
|
|
8) Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340: 115-26
|
|
|
|
|
|
9) Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science. 2001; 293: 1673-7
|
|
|
|
|
|
10) Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000; 275: 9047-54
|
|
|
|
|
|
11) Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002; 420: 333-6
|
|
|
|
|
|
12) Cai D, Yuan M, Frantz, DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK- and NF-B. Nat Med. 2005; 11: 183-90
|
|
|
|
|
|
13) Lee JY, Sohn KH, Rhee SH, et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001; 276: 16683-9
|
|
|
|
|
|
14) Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006; 116: 3015-25
|
|
|
|
|
|
15) Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752-61
|
|
|
|
|
|
16) Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-61
|
|
|
|
|
|
17) Hung JH, Su IJ, Lei HY, et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem. 2004; 279: 46384-92
|
|
|
|
|
|
18) Gao Z, Zhang X, Zuberi A, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004; 18: 2024-34
|
|
|
|
|
|
19) Aguirre V, Werner ED, Giraud J, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002; 277: 1531-7
|
|
|
|
|
|
20) Werner ED, Lee J, Hansen L, et al. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem. 2004; 279: 35298-305
|
|
|
|
|
|
21) Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med. 2004; 10: 1128-32
|
|
|
|
|
|
22) Yin MJ, Yamamoto Y, Gaynor RB, et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998; 396: 77-80
|
|
|
|
|
|
23) Hundal RS, Petersen KM, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002; 109: 1321-6
|
|
|
|
|
|
24) Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796- 808
|
|
|
|
|
|
25) Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-30
|
|
|
|
|
|
26) Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. FASEB J. 1995; 9: 899-909
|
|
|
|
|
|
27) Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094-9
|
|
|
|
|
|
28) Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003; 100: 7265- 70
|
|
|
|
|
|
29) Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006; 116: 1494-505
|
|
|
|
|
|
30) Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006; 281: 26602-14
|
|
|
|
|
|
31) Inouye KE, Shi H, Howard JK, et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes. 2007; 56: 2242-50
|
|
|
|
|
|
32) Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006; 116: 115- 24
|
|
|
|
|
|
33) Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006; 43: S54-62
|
|
|
|
|
|
34) Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11: 191-8
|
|
|
|
|
|
35) Rohl M, Pasparakis M, Baudler S, et al. Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest. 2004; 113: 474-81
|
|
|
|
|
|
36) Cai D, Frantz JD, Tawa NE, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004; 119: 285-98
|
|
|
|
|
|
37) Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006; 166: 902-8
|
|
|
|
|
|
38) Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005; 42: 517-25
|
|
|
|
|
|
39) Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998; 391: 79-82
|
|
|
|
|
|
40) Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005; 437: 759-63
|
|
|
|
|
|
41) Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103: 357-62
|
|
|
|
|